Full Papers
A retrospective analysis of colchicine in combination with NSAIDs therapy in patients with systemic form of adult-onset Still's disease with serositis
V. Myachikova1, O. Moiseeva2, A. Konradi3, S.V. Lapin4, O. Tkachenko5, V. Nazarov6, E. Feist7, A. Maslyanskiy8
- Almazov National Medical Research Centre, Saint Petersburg, Russia. myachikova_vyu@almazovcentre.ru
- Almazov National Medical Research Centre, Saint Petersburg, Russia.
- Almazov National Medical Research Centre, Saint Petersburg, Russia.
- Center for Molecular Medicine, First Pavlov State Medical University of Saint Petersburg, Russia.
- Center for Molecular Medicine, First Pavlov State Medical University of Saint Petersburg, Russia.
- Center for Molecular Medicine, First Pavlov State Medical University of Saint Petersburg, Russia.
- Department of Rheumatology, Helios Clinic, cooperation partner of the Otto-von-Guericke-University and Rheumazentrum e.V., Magdeburg, Germany.
- Almazov National Medical Research Centre, Saint Petersburg, and Saint Petersburg State University, Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology, St. Petersburg, Russia.
CER15064
2022 Vol.40, N°8
PI 1474, PF 1479
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 35084308 [PubMed]
Received: 10/08/2021
Accepted : 15/11/2021
In Press: 12/01/2022
Published: 14/09/2022
Abstract
OBJECTIVES:
Adult-onset Still’s disease (AOSD) is increasingly viewed as autoinflammatory disease associated with the so-called inflammasomopathy. Proinflammatory cytokines, such as IL-18 and IL-1β, processed through the inflammasome machinery, play an important role in the pathogenesis of AOSD. AOSD is heterogenous, therefore there are two subtypes of the disease, systemic and articular, which probably imply different approaches for the treatment. Over 20% of patients with systemic AOSD have serositis. Recently, colchicine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) has become the “gold standard” for recurrent pericarditis treatment. However, data on this combination therapy in AOSD are scarce.
METHODS:
In this retrospective case series study, we assessed the medical history of 20 patients with a systemic form of AOSD. All patients had pericarditis and received а combination of NSAIDs (in most cases ibuprofen 600-800 mg x3 daily) and colchicine (1 mg daily) for treatment.
RESULTS:
13/20 (65%) of patients responded to this combination of anti-inflammatory drugs. Of note, not only pericarditis, but also other manifestations were improved such as arthritis, rash, hepatomegaly, acute phase reactants, and abnormal liver tests.
CONCLUSIONS:
The low cost, safety and wide availability of such therapy make this option relevant and determine the need for further study.
